Aeterna Zentaris Inc. (AEZS) and Acer Therapeutics Inc. (NASDAQ:ACER) Contrasting side by side

Both Aeterna Zentaris Inc. (NASDAQ:AEZS) and Acer Therapeutics Inc. (NASDAQ:ACER) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aeterna Zentaris Inc. 2.26M 21.20 15.15M 0.25 13.17
Acer Therapeutics Inc. N/A 0.00 25.27M -2.45 0.00

Table 1 shows the gross revenue, earnings per share (EPS) and valuation for Aeterna Zentaris Inc. and Acer Therapeutics Inc.

Profitability

Table 2 demonstrates the return on equity, return on assets and net margins of Aeterna Zentaris Inc. and Acer Therapeutics Inc.

Net Margins Return on Equity Return on Assets
Aeterna Zentaris Inc. -670.35% 116.3% 29.1%
Acer Therapeutics Inc. 0.00% -65.1% -59.2%

Volatility & Risk

Aeterna Zentaris Inc.’s 1.26 beta indicates that its volatility is 26.00% more volatile than that of Standard & Poor’s 500. Competitively, Acer Therapeutics Inc.’s 141.00% volatility makes it more volatile than Standard & Poor’s 500, because of the 2.41 beta.

Liquidity

Aeterna Zentaris Inc.’s Current Ratio and Quick Ratio are 2.9 and 2.9 respectively. The Current Ratio and Quick Ratio of its competitor Acer Therapeutics Inc. are 7.7 and 7.7 respectively. Acer Therapeutics Inc. therefore has a better chance of paying off short and long-term obligations compared to Aeterna Zentaris Inc.

Analyst Recommendations

In next table is shown Aeterna Zentaris Inc. and Acer Therapeutics Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Aeterna Zentaris Inc. 0 0 0 0.00
Acer Therapeutics Inc. 0 0 2 3.00

Acer Therapeutics Inc. on the other hand boasts of a $44 consensus target price and a 161.90% potential upside.

Insider & Institutional Ownership

Aeterna Zentaris Inc. and Acer Therapeutics Inc. has shares owned by institutional investors as follows: 21.4% and 60.5%. Aeterna Zentaris Inc.’s share owned by insiders are 0.6%. Competitively, 0.1% are Acer Therapeutics Inc.’s share owned by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Aeterna Zentaris Inc. -1.48% -25.89% -18.43% 46.9% 78.49% 12.93%
Acer Therapeutics Inc. 16.33% -12.58% -7.56% -9.63% 22.47% 11.88%

For the past year Aeterna Zentaris Inc. has stronger performance than Acer Therapeutics Inc.

Summary

Aeterna Zentaris Inc. beats Acer Therapeutics Inc. on 8 of the 11 factors.

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women's health. The companyÂ’s product pipeline includes Zoptrex, which completed Phase III clinical study for women with advanced, recurrent, or metastatic endometrial cancer, as well as in various phases for the treatment of ovarian and prostate cancer; and MACRILEN, which completed Phase III trial for use in the diagnosis of adult growth hormone deficiency. It is also developing an LHRH-disorazol Z conjugate, which is in pre-clinical development in oncology. Aeterna Zentaris Inc. was founded in 1991 and is headquartered in Summerville, South Carolina.

Acer Therapeutics Inc. develops therapies for the treatment of serious ultra-rare diseases with critical unmet medical needs. The company offers Celiprolol for vascular ehlers-danlos syndrome and ACER-001 for maple syrup urine disease (MSUD). It also offers advancing ACER-001 for the treatment of urea cycle disorders (UCD). The company was founded in 2013 and is based in Cambridge, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.